Targeted drug combo for HER2-positive breast cancer with brain mets
Part of Cancer, Skin clinical trials.
This trial tests a combination of targeted drugs (Disitamab Vedotin plus either Pyrotinib or Neratinib) for people with HER2-positive breast cancer that has spread to the brain. The goal is to see if this treatment can help shrink brain tumors or slow their growth.
Summary written for real people, not researchers, by Clin2.
Who can take part
- You are 18 or older.
- You have HER2-positive breast cancer that has spread to the brain.
- Your brain tumors are either newly found or have grown after earlier radiation treatment.
- You have not already received an anti-HER2 antibody-drug conjugate or both pyrotinib and neratinib before.
- Your heart, blood, liver, and kidney function are within healthy ranges (checked by doctors).
Quick eligibility check
Answer a few plain-language questions, based on this study's own requirements, to get a preliminary sense of fit.
Similar studies
Other trials that look related to this one.
This trial tests a combination of two targeted drugs (Disitamab Vedotin and Pyrotinib) for people with HER2-positive early breast cancer. It aims to see if this treatment can improve outcomes before standard therapy.
This trial tests a new combination of targeted drugs (Disitamab Vedotin and RC148) against a standard chemotherapy (Abraxane) with or without an immunotherapy drug (Toripalimab) for advanced breast cancer that is HER2-low and hormone receptor-negative. The goal is to see if the new combination works better at shrinking tumors and slowing cancer growth.
This study tests whether neratinib plus capecitabine can slow or shrink breast cancer that has spread to the brain. It is for people whose cancer shows an “overactive HER2 signal” on a specific tumor test, even though their cancer is labeled HER2-negative.
This trial tests a combination of two targeted therapies, Trastuzumab Deruxtecan (T-DXd) and Pyrotinib, as a first treatment for HER2-positive breast cancer that has spread or cannot be removed. It aims to see if this combination works better than standard treatments.
This trial tests two new drugs, SHR-A1811 and THPy, in people with HER2 positive advanced breast cancer that has spread to the brain. It is for those who have not received any previous treatment for advanced cancer.
This trial tests a combination of two drugs (disitamab vedotin and toripalimab) followed by chemotherapy before surgery for people with a specific type of breast cancer that is hormone receptor-positive and HER2-low. The goal is to see if this treatment can shrink the tumor and improve outcomes.
Hear when a new Breast cancer trial opens
We’ll email you when one opens — at most once a week, no account needed, unsubscribe anytime.